Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus

Hormone and Metabolic Research

Volumn 29, Issue 9, 1997, Pages 411-416

  Nauck, M A ^a   Hoist, J ^a,b   Willms, B ^a,c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Fachklinik für Diabetes und Stoffwechselkrankheiten   (Germany)

Author keywords

Gastric emptying; Glucacon; Glucagon like peptide 1; Insulin; Type 2 diabetes

Indexed keywords

ACARBOSE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; METFORMIN; PEPTIDE FRAGMENT; PROTEIN PRECURSOR; SULFONYLUREA DERIVATIVE; TRISACCHARIDE;

AGED; ARTICLE; BLOOD; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; REGRESSION ANALYSIS; ADULT; CLINICAL ARTICLE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE REGRESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ACARBOSE; AGED; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; METFORMIN; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; REGRESSION ANALYSIS; SULFONYLUREA COMPOUNDS; TRISACCHARIDES;

EID: 0030613750     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979067     Document Type: Article

References (55)

1. Bell. C. I., R. Sanchez-Pescador. P.J. Layboum. R. C. Najarian: Exon duplication and divergence in the human proglucagon gene. Nature 304: 368-371 (1983)
2. Creutzfeld, W.: The incretin concept today. Diabetologia 16: 75-85(1975)
3. Creutzfeldt. W., N. Kleine. B. Willms. C. Ørskov, J. J. Holst, M. A. Nauck: Clucagonostatic actions and reduction of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 1 (insulin-dependent) - diabetic patients. Diabetes Care 19:580-586(1996)
4. Deacon, C. F., M. A. Nauck, M. Toft-Nielsen. L. Pridal, B. Willms: Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2 diabetic patients and in healthy subjects. Diabetes 44: 1126-1131(1995)
5. Defronzo, R. A.: The triumvirate: -cell, muscle, liver. A collusion responsible for N1DDM. Diabetes 37: 667-687 (1988)
6. Dupre.J., M. T. Behme. I. M. Hramiak, P. McFarlane, M. P. Williamson. P. Zabel, T. J. McDonald: Glucagon-like peptide 1 reduces postprandial glycémie excursions in IDDM. Diabetes 44: 626-630(1995)
7. Eissele, R., R. Coke, S. Willemer. H.-P. Harthus, H. Vermeer, R. Arnold, B. Coke: Glucagon-like peptide 1 cells in the gastrointestinal tract and pancreas of rat, pig and man. EurJ din Invest 22: 283-291 (1992)
8. Elahi, D., M. McAllon-Dyke, N. K. Fukagawa, G. S. Meneilly, A. L Sclater, K. L Minaker, J. F. Habener, D. K. Andersen: The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51: 63-74 (1994)
9. Elrick, H., L Stimmler, C. K.J. Hlad, Y. Arai: Plasma insulin response to oral and intravenous glucose administration.] Clin Endocrinol Metab24: 1076-1082(1964)
10. Fehmann, H.-C.,J. F. Habener: Insulinotropic hormone glucagonlike peptide-1 (7-37) stimultion of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells. Endocrinol 130:159-166(1992)
11. Fieseler, P., S. Bridénbaugh, R. Nustede, ]. Marte//, C. Orskov, ]. J. Hoist, M. A. Nauck: Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-1 but not by CCK-8. Am J Physiol 268: E949-955 (1995)
12. Frank,]. W., S. B. Saslow, M. Camilleri. C. M: Tlwmforde, S. Dinneen, R. A. Rizza: Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type 2 diabetes mellitus. Castroenterol 109: 755-765 (1995)
13. Furnsinn. C, K. Ebner. W. Waldhäusl: Failure of GLP-1 (7-36) amide to affect glycogenesis in rat skeletal muscle. Diabetologia 38:863-867(1995)
14. Geric/i, J. £.: Abnormal glucagon secretion in type 2 (noninsulindependent) diabetes mellitus: causes and consequences. In: Diabetes mellitus: Pathophysiology and therapy, Creutzfeldt, W., P. Lefèbvre eds.. Springer, Berlin, Heidelberg. 127-133 (1989)
15. Cutniak, M., C. 0rskov,J.J. Holst, B. Ähren, S. Efendic: Antidiabetogenic effect of glucagon-like peptide-1 (7-36 amide) in normal subjects and patients with diabetes. N Engl J Med 326: 13161322(1992)
16. Hoist. J. J.. C. 0rskov, 0. Vagn /Vie/sen. T. W. Schwanz: Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEES Letters 211: 169 -174 (1987)
17. Johnson, 0. F. L,J. L Cleleand, H.J. Lee, M. Chamis, E. Duenas, W.Javvorovvicz, D. Shepard, A. Shahzamani, A.J. S.Jones. S. D. Putney: A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med 2: 795-799 (1996)
18. Kavvai, K., S. Suzuki, S. Ohashi, H. Mutai, H. Ohmori, Y. Murayama, K. Yamashita: Comparison of the effects of glucagon-like peptidel-(l-37) and -(7-37) and glucagon on islet hormone release from the isolated perfused canine and rat pancreases. Endocrinol 124:1768-1773(1989)
19. Kolligs. F., H.-C. Fehmann. R. Coke, B. Coke: Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44:16-19 (1995)
20. Kreymann, B., M. A. Ghatei, G. Williams. S. R. Bloom: Glucagon-like peptide-1 17-36: a physiological incretin in man. Lancet II: 1300-1304(1987)
21. Layer, P..J. H. Hoist, D. Crandt, H. Coebell: Heal release of glucagonlike peptide-1 (GLP-1 ). Association with inhibition of gastric acid secretion in humans. Dig Dis Sei 40:1074-1082 (1995)
22. topez, L C, M. L Frazier, C.-J. Su, A. Kumar, G. E Sounders: Mammalian pancreatic proglucagon contains three glucagon-related peptides. Proc Natl Acad Sei USA 80: 5485-5489 (1983)
23. Nathan, D. M., E. Schreiber, H. Fogel, S. Mojsov, J. F. Habener: Insulinotropic action of glucagon-like peptide-l-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15: 270-276 (1992)
24. Nauck, M. A., E. Hornberger, E. G. Siegel, R. C. Allen, R. P. Eaton, R. Ebert, W. Creutzfeld: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498 (1986)
25. Nauck, M., E. Bartels, C. Orskov, R. Ebert, W. Creutzfeldt: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 (7-36 amide) infused at near-physiological insulinotropic hormone and glucose concentrations.] Clin Endocrinol Metab 76: 912-917 (1993)
26. Nauck, M. A.. M. M. Heimesaat. C. Orskov, J. J. Hoist. R. Ebert. W. Creutzfeldt: Preserved incretin activity of glucagon-like peptide 1 (GLP-1) (7-36 amide) but not of synthetic human gastric inhibitory polypeptide (GIP) in patients with type 2 diabetes mellitus. J Clin Invest 91: 301 -307 (1993)
27. Nauck, M. A.. N. Kleine, C. Orskov, J.J. Hoist, B. Willms, W. Creutzfeldt: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1(7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741 -744 (1993)
28. Nauck, M. A. D. Wollschläger, J. Werner. J. J. Hoist. C. Orskov. W. Creutzfeldt. B. Willms: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39:1546-1553(1996)
29. Nauck, M. A, R. Ettler, U. Niedereichholz, C. Orskov, J. J. Holst, W. Schmieget: Inhibition of gastric emptying by GLP-1 (7-36 amide) or (7-37): effects on postprandial glycaemia and insulin secretion in man (abstract). Gut 37 (Suppl. 2): A124 (1995)
30. 0/i/son, L-0., B. tarsson, K. Svärdsudd, L We/in, H. Eriksson, L Wilhelmsen, P. Bjömtorp, G. Tibblin: The influence of body fat distribution on the incidence of diabetes mellitus. Diabetes 34: 1055-1058(1985)
31. 0rsfcov, C..J.J. Hoist: Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). ScandJ Clin Lab Invest 47:165174(1987)
32. 0rskov, C.J.J. Hoist, 0. V. Nielsen: Effect of truncated glucagon-like peptide-1 (proglucagon 78-101 amide) on endocrine secretion from pig pancreas, antrum and non-antral stomach. Endocrinology 23: 2009-2013(1988)
33. 0rskov, C, M. Bersoni, A H.Johnsen, P. HojrupJ.J. Holst: Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J. Biol. Chem. 264:12826-12829 (1989)
34. 0rskov, C, L Rabenhq/, A Wettergren, H. Kofod.J.J. Holst: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43:535-539(1994)
35. 0rskov, C..J.J. Holst, J. Moller, C. Orskov, N. Moller. K. G. M. M. Alberti, 0. Schmilz: GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39: 1227-1232 ( 1996)
36. Perley, M.)., D. M. Kipnis: Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects.] Gin Invest 46:1954-1962(1967)
37. Qualmann, C, M. A. Nauck. J. J. Hoist. C. 0rskov, W. Creutzfeldt: Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) (7-36 amide) in the fasting state in healthy subjects. Acta Diabetol 32:13-16(1995)
38. RahierJ.. R. M. Goebbels,}. C. Henquin: Cellular composition of the human diabetic pancreas. Diabetologia 24:366-371 (1983)
39. RahierJ. R. D., M. Ibrahim, K. Channaoui: Islet cell populations in obese subjects and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 32: 532 A (abstract) (1989)
40. Ritzel, R..J.J. Holst, C. Orskov, M. A. Nauck: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38: 720-725 (1995)
41. Scrocchi, L A., T. J. Brown, N. Maclusky, P. L Brubaker, A. B. Auerbach, A. LJoyner, D.J. Drucker: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Medicine 2:1254-1258 (1996)
42. SchirraJ., P. Kuwert, U. Wank, P. Leicht, R. Arnold, B. Cöke, M. Katschinski: Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility and pancreatic function in men. Proc. Ass. Am. Phys. 109: 84-97 (1997)
43. Tillil, H., E. T. Shapiro, M. A. Miller, T. Karrison, B. H. Frank,]. A. Galloway, A. Rubenstein, K. S. Polonsky: Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. AmJ Physiol (Endocrinol Metab) 254: E349357(1988)
44. Toft-Nielsen, M. S. Madsbad.J.J. Holst: The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45: 552-556(1996)
45. Turton, M. D., D. O'Shea, I. Gunn, S. A. Beak, C. M. B. Edwards, K. Meeran, S.J. Choi, G. M. Taylor, M. M. Heath, P. D. Lambert,]. P. H. Wilding, D. M. Smith, M. A. Ghatei.J. Herbert, S. R. Bloom: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72 (1996)
46. Valverde, L, M. L Villanueva-Penacarillo: Target tissues for GLP-1 (7-36 amide). Digestion 54: 343 (1993)
47. Vamdelt. I. M., A. E. Bis/op. K. L Sikri. L 0. Uttenthal. S. R. Bloom.]. M. Polak: Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. J. Histochem. Cytochem 33: 1080-1086(1985)
48. Wang. Z, R. M. Wang, A. A. Owij, D. M. Smith, M. A. Ghatei, S. R. Bloom: Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95: 417-421 (1995)
49. Weber, J., A. K. Bach-Esser, 1. Bach, S. Richter, C. 0rskov,J.J. Holst, W. Schmieget, M. A. Nauck: Prolonged normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2-diabetic patients (abstract). Diabetologia 38 (Suppl. 1): A171 (1995)
50. so wettergen, A., B. Schjoldager, P. E. Mortensen.J. Myhre.J. Christiansen, J.J. Hoist: Truncated GLP-1 (proglucagon 87- 107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sei 38: 665-673(1993)
51. Weir, G. C, S. Mojsov, G. K. Hendrick,]. F. Habener: Glucagon like peptide I (7-37) actions on endocrine pancreas. Diabetes 38: 338-342(1989)
52. Willms. B., K. Idowu,].]. Holst, M. A. Nauck: Overnight GLP-1 (736 amide), daytime oral agents: Failure to lower postprandial glucose by normalizing fasting values in NIDDM patients, (abstract) Diabetes 45 (Suppl. 2): A301
53. WiHms, B.J. Werner. C. 0rskov,J.J. Holst, W. Creutzfeldt. M. Nauck: Gastric emptying, glucose response, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-Iike peptide-1 (GLP-1 )-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.] Clin Endocrinol Metab 81: 327-332 (1996)
54. Wrighton, N. C, E X. Farrell, R. Chang. A. K. Kashyab. F. B. Barbone, L S. Mulcahy, D. L Johnson. R. W. Barrett, L K.Jolliffe, W.J. Dower. Small peptides äs potent mimetics of the protein hormone erythropoietin. Science 273:458 -463 (1996)
55. Yki-Järvinen, H.: Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 38:1378-1388 (1995)